Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.74 |
| ▸ | PIM1 | P11309 | 2/20 | 0.74 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.74 |
| ▸ | AKT1 | P31749 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.64 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.64 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.63 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.56 |
| ▸ | IP6K3 | Q96PC2 | 5/20 | 0.54 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29605527 | 1.00 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL13820309 | 0.88 | PARP1 (0.78) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL1690531 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL29967230 | 0.85 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL17586152 | 0.82 | PARP1 (0.70) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL8622180 | 0.81 | ACVR1 (0.73) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL3742786 | 0.79 | ACVR1 (0.65) | PARP1CHEK1PIM1RPS6KA3AKT1 | |
| SCHEMBL642178 | 0.78 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL2081677 | 0.78 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 | |
| SCHEMBL2191067 | 0.78 | PARP1 (1.00) | PARP1CHEK1PIM1AKT1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101857617-A | Quinazoline sugar derivative and preparation method and application thereof | OCEAN UNIV CHINA | 2010-10-13 | — | — | CN | claimed |
| CN-117946012-A | Preparation method of nitrogen-containing heterocycle | 温州理工学院 | 2024-04-30 | — | — | CN | disclosed |
| US-20240034723-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-02-01 | — | — | US | disclosed |
| CN-114807987-B | Electrochemical method for preparing fused polycyclic quinazolinone derivative | 哈尔滨工业大学（深圳） | 2023-10-03 | — | — | CN | disclosed |
| CN-116669769-A | Piperidinyl small molecule degradants of HELIOS and methods of use | 达纳－法伯癌症研究所公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-114621194-B | 4-methylene-N-hydroxybenzoamide compound and application thereof | 沈阳药科大学 | 2023-08-29 | — | — | CN | disclosed |
| EP-4228651-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | GAIN THERAPEUTICS SA (CH) | 2023-05-04 | — | — | US | disclosed |
| CN-113637011-B | Myricetin derivative containing quinazoline-4 (3H) -ketone and preparation method and application thereof | 贵州大学 | 2023-03-31 | — | — | CN | disclosed |
| WO-2023274246-A1 | AMIDE COMPOUND AND USE THEREOF | 成都分迪药业有限公司 | 2023-01-05 | — | — | WO | disclosed |
| CN-1137037-A | Quinazoline derivatives | PFIZER (US) | 1996-12-04 | — | — | CN | disclosed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0566226-B1 | Quinazoline derivatives | ZENECA LTD (GB) | 1995-11-08 | — | — | EP | disclosed |
| US-5457105-A | anticancer use; e.g. 4-(3'-chloro-4'-fluoroanilino)-6,7-dimethoxyquinazoline (gefitinib) | ZENECA LIMITED (GB) | 1995-10-10 | — | — | US | disclosed |
| WO-1995024190-A2 | RECEPTOR TYROSINE KINASE INHIBITORS FOR INHIBITING CELL PROLIFERATIVE DISORDERS AND COMPOSITIONS THEREOF | SUGEN, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0566226-A1 | Quinazoline derivatives | ZENECA LIMITED (GB) | 1993-10-20 | — | — | EP | disclosed |
| US-5236927-A | Reduced toxicity; side effect reduction | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0204529-B1 | ANTI-CANCER QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| EP-0204529-A2 | Anti-cancer quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 1986-12-10 | — | — | EP | disclosed |
| US-4223143-A | PYRAZOLO-QUINAZOLIN-ONES, CONTROLLING URIC ACID CONCENTRATION, GOUT, XANTHINE OXIDASE | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1980-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140216-A1 | COMBINATION THERAPY FOR TREATING MPS1 | IDUA, MAN2B1, GBA1 | PARP1 3379/4885CHEK1 4632/4885PIM1 1672/4885 |
| US-20240034723-A1 | PIPERIDINYL SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | PARP1 1121/4885CHEK1 3435/4885PIM1 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.